HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
XENE
Xenon Pharmaceuticals Inc.
There isn't enough reported data to score XENE yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
XENE Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
XENE's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
XENE PE Valuation
XENE has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
XENE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect XENE's revenue to grow, with its earnings and profitability holding steady.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over XENE on earnings, with more consistent year-over-year improvement.
XENE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$4.70 | -$0.82 |
| Q2 2026 | -$4.74 | -$1.20 |
| Q1 2026 | -$4.70 | -$1.48 |
| Q4 2025 | -$4.36 | -$1.35 |
| Q3 2025 | -$3.88 | -$1.05 |
| Q2 2025 | -$3.54 | -$0.79 |
| Q1 2025 | -$3.22 | -$0.50 |
| Q4 2024 | -$3.01 | -$0.28 |
XENE lost $4.70 per share over the past year, a bigger loss than the year before.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over XENE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
XENE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2022 | $132K | -98% |
| Q2 2022 | $536K | -76% |
| Q1 2022 | $8.8M | +101% |
| Q4 2021 | $3.7M | -27% |
| Q3 2021 | $8.1M | +24% |
| Q2 2021 | $2.2M | -83% |
| Q1 2021 | $4.4M | -38% |
| Q4 2020 | $5.2M | +55% |
XENE's revenue has slid since its 2020 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2025 | -970% | N/A |
| Q3 2022 | -28885% | -28693 points |
| Q2 2022 | -5656% | -4641 points |
| Q1 2022 | -198% | +170 points |
| Q4 2021 | -665% | -414 points |
| Q3 2021 | -192% | -44 points |
| Q2 2021 | -1014% | -1010 points |
| Q1 2021 | -368% | -255 points |
XENE's operating margin was −970% last quarter, down 305 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over XENE on cash generation, producing positive trailing cash flow while its opponent burns cash.
XENE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$90.6M | -$18.6M |
| Q2 2026 | -$95.7M | -$31.3M |
| Q1 2026 | -$89M | -$27.3M |
| Q4 2025 | -$81.8M | -$26.6M |
| Q3 2025 | -$72M | -$20.3M |
| Q2 2025 | -$64.4M | -$30.2M |
| Q1 2025 | -$61.7M | -$18.3M |
| Q4 2024 | -$55.2M | -$19.6M |
XENE has burned cash in almost every quarter: −$357M over the past year, against −$253M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over XENE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
XENE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +156K shares |
| 1 year | +26% | +20.5M shares |
| 3 years | +51% | +33.8M shares |
| 5 years | +142% | +58.6M shares |
| Available history | +201% | +66.6M shares |
XENE has 100M diluted shares, up 26% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
XENE Net Leverage
XENE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
XENE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.9 | Neutral |
| Stochastic | 17.7 | Oversold |
XENE's weekly RSI is 40 (neutral) and its Stochastic is 18 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
XENE PE vs Healthcare Sector
XENE has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
XENE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $37.2 | 10% above |
| 20 week MA | $51.4 | 20% below |
| 50 week MA | $50.3 | 18% below |
| 100 week MA | $43.4 | 5.4% below |
| 200 week MA | $41.5 | 1.3% below |
XENE has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
XENE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $13.4 | $15.3 | +14% |
| 2021 | $15.3 | $30.5 | +100% |
| 2022 | $30.5 | $38.1 | +25% |
| 2023 | $38.1 | $46.1 | +21% |
| 2024 | $46.1 | $38.8 | -16% |
| 2025 | $38.8 | $44.8 | +15% |
| 2026 YTD | $44.8 | $41.0 | -8.6% |
XENE has the edge over HIMS on returns for 2026, with the stronger performance.